MN_001



NAME OF DRUG : MN_001

ALSO KNOWN AS : TIPELUKAST

LABORATORY : MEDICINOVA

STATUS AND ADVANCEMENT

Type of drug : (5-LOLT) inibitor

Clinical trials advancement : Analysing Results Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated time to market : 88 months.

LABORATORY ABSTRACT ON THE DRUG

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001’s inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models. Previously, MediciNova evaluated MN-001 for its potential clinical efficacy in asthma and had positive Phase 2 results. MN-001 has been exposed to more than 600 subjects and considered generally safe and well-tolerated.

RECENT NEWS ON MN_001

SOME PUBLICATIONS RELATED WITH MN_001

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH MN_001


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE